Category: Uncategorized

Sleep Apnea and TRT Practical Care for Hypogonadal Men

Posted on by Taurus

Sleep Apnea and TRT Practical Care for Hypogonadal Men

Untreated sleep apnea can lower testosterone and complicate TRT. See when to prioritize CPAP, how to dose conservatively, and what labs and symptoms to monitor.

Estimated reading time: 10 minutes

Key takeaways

  • Untreated OSA can contribute to secondary hypogonadism via intermittent hypoxia and sleep fragmentation.
  • Most guidance prioritizes treating moderate–severe OSA (e.g., CPAP) before initiating TRT.
  • TRT can worsen sleep-disordered breathing in susceptible men, especially with supraphysiologic dosing or early in therapy.
  • CPAP often improves total testosterone and erectile function, sometimes independent of weight loss.
  • OSA and TRT both can raise hematocrit and influence blood pressure—monitor closely and dose conservatively.

Table of contents

  1. Does Sleep Apnea Complicate TRT? Diagnosis and Management in Hypogonadal Men
  2. How Obstructive Sleep Apnea Affects Testosterone
  3. Can TRT Worsen Sleep Apnea?
  4. Sequencing Care: CPAP First, Then Reassess Testosterone
  5. Monitoring Overlaps: Hematocrit, Blood Pressure, and Sleep Quality
  6. Sexual Function: CPAP, TRT, or Both?
  7. Practical Signs That You Should Revisit Your Plan
  8. Special Considerations and Adjacent Levers
  9. How Taurus Meds Approaches TRT in the Context of Sleep Apnea
  10. What We Still Don’t Know (Yet)
  11. Conclusion

Does Sleep Apnea Complicate TRT? Diagnosis and Management in Hypogonadal Men

Many men pursuing testosterone replacement therapy (TRT) also live with undiagnosed or untreated obstructive sleep apnea (OSA). The overlap matters. Untreated OSA can lower testosterone and mimic or worsen hypogonadal symptoms, while TRT may exacerbate sleep-disordered breathing or raise hematocrit, a risk also seen with OSA itself. Understanding this two-way relationship helps set realistic expectations and safer treatment plans.

How Obstructive Sleep Apnea Affects Testosterone

OSA fragments sleep and repeatedly lowers oxygen levels overnight. Both processes are unfavorable for testosterone production, which relies on consolidated sleep and normal hypothalamic–pituitary–gonadal signaling. Across observational studies, apnea severity (e.g., higher apnea–hypopnea index and oxygen desaturation index) correlates with lower total testosterone, even after accounting for BMI.

Why this matters if you have low T:

  • OSA can be a hidden driver of secondary hypogonadism, especially in men with snoring, witnessed apneas, morning headaches, or daytime sleepiness.
  • Treating OSA with continuous positive airway pressure (CPAP) often improves total testosterone and energy, and can modestly improve body composition and sexual function in some men.
  • In several cohorts, CPAP improved testosterone levels independent of weight loss—so it is not only weight change explaining the hormone shift.

If you feel “low T” symptoms plus classic OSA features, the sleep disorder may be part of the root cause.

Can TRT Worsen Sleep Apnea?

The relationship appears bidirectional. Mechanistically, testosterone can influence upper airway muscle tone, ventilatory responses to hypoxia and hypercapnia, and oxygen demand—all of which may worsen sleep-disordered breathing in vulnerable individuals. Observational data suggest TRT users may have a higher incidence of OSA diagnoses over time compared to non-users (one cohort reported 16.5% vs 12.7% at two years). Not all studies agree, and confounding by obesity and comorbidities is common.

Important nuances:

  • Dose and duration matter. Short-term, higher-dose regimens are more likely to aggravate apnea indices than physiologic, steady-state replacement.
  • Not every man on TRT develops or worsens OSA, but new or louder snoring, unrefreshing sleep, morning headaches, or bed-partner reports of pauses in breathing after starting therapy warrant attention.
  • Current guidance typically lists severe, untreated OSA as a contraindication to initiating TRT. European recommendations have softened the stance slightly, focusing on risk assessment and monitoring rather than absolute prohibition, but the principle remains: address significant OSA first.

Sequencing Care: CPAP First, Then Reassess Testosterone

For men with low testosterone levels and suspected or known OSA, a pragmatic sequence often helps:

  1. Screen for OSA if low T is present—especially in men with snoring, obesity, resistant hypertension, or daytime sleepiness. When suspicion is high, formal sleep testing (e.g., polysomnography or home sleep apnea testing as appropriate) is usually warranted.
  2. Prioritize OSA treatment if moderate-to-severe disease is found. CPAP is the mainstay, alongside weight management and addressing nasal or airway contributors when relevant.
  3. Reassess symptoms and testosterone after OSA therapy is established. Many men experience improved energy, libido, and even testosterone levels on effective CPAP.
  4. If hypogonadism persists (confirmed by morning total testosterone, ideally on two separate days with appropriate lab technique), consider TRT with careful oversight.
  5. If TRT is started, continue OSA therapy without interruption, and monitor for changes in sleep quality, snoring, and oxygenation. Adjust TRT dosing to maintain physiologic targets, not supraphysiologic peaks.

Why this order? It reduces the chance of TRT aggravating untreated sleep-disordered breathing, and it may spare some men from needing TRT at all. It also provides a clearer baseline for monitoring hematocrit and blood pressure once TRT begins.

Monitoring Overlaps: Hematocrit, Blood Pressure, and Sleep Quality

Hematocrit and erythrocytosis:

  • Both OSA (via chronic hypoxia) and TRT can raise hematocrit. Clinical trials suggest TRT increases hematocrit by roughly 3% on average, but individual responses vary widely.
  • Many clinicians monitor hematocrit at baseline, again at 3–6 months after starting or changing dose, and then periodically. Men with OSA or prior high hematocrit may need closer follow-up.
  • If hematocrit rises substantially (for example, approaching or exceeding ~52%), clinicians often consider dose adjustments, addressing OSA adherence, evaluating for other hypoxic drivers (e.g., altitude, smoking), or therapeutic phlebotomy.

Blood pressure:

  • OSA commonly contributes to hypertension.
  • In February 2025, the FDA removed the boxed warning on major adverse cardiac events from testosterone labeling but added a class-wide blood pressure warning based on ambulatory monitoring data. Practically, this means blood pressure deserves routine attention before and during TRT.
  • Expect your care team to check and manage blood pressure throughout therapy.

Sleep quality and hypoxia:

  • If TRT is introduced, watch for new or worsening snoring, gasping, nocturia, nonrestorative sleep, or morning headaches.
  • Bed-partner observations can be invaluable. Consumer wearables and smartphone oximetry are not diagnostic but can prompt timely conversations if trends worsen.
  • If CPAP adherence slips, apnea can worsen—and so can hematocrit and blood pressure. Work with your sleep team on mask fit and comfort.

Sexual Function: CPAP, TRT, or Both?

  • Erectile dysfunction (ED) and low libido are common in both OSA and hypogonadism. CPAP alone improves ED in a substantial share of men with OSA, even when testosterone does not rise meaningfully.
  • In men with persistent hypogonadism after OSA treatment, combining CPAP and TRT may further improve sexual function compared to either alone.
  • If your primary goal is sexual health, optimizing sleep first often pays dividends and may clarify how much additional benefit TRT can offer.

Practical Signs That You Should Revisit Your Plan

Whether you’re considering TRT or already on therapy, bring these changes to your clinician’s attention:

  • New or louder snoring, witnessed apneas, or choking/gasping at night
  • Morning headaches, unrefreshing sleep, or daytime sleepiness that starts or worsens after TRT
  • Rising hematocrit on routine labs, especially alongside snoring or high-altitude exposure
  • Blood pressure creeping up after starting TRT
  • Poor CPAP comfort or adherence

Small course corrections—optimizing CPAP, adjusting TRT dose or formulation, tackling nasal congestion, or reevaluating sleep severity—can restore balance.

Special Considerations and Adjacent Levers

  • Weight management: Many men with “low T + OSA” also have central obesity. Sustained weight loss improves both sleep apnea severity and testosterone biology. Emerging anti-obesity medications (e.g., GLP-1–based therapies) may help reduce AHI and improve metabolic health, though long-term data on testosterone and sleep outcomes remain limited.
  • Formulation and dosing: Steady, physiologic replacement is the goal. Short-acting formulations or regimens that avoid large peaks may be preferable if apnea worsens with higher serum swings. Personalization and monitoring matter more than brand or route.
  • Lifestyle and environment: Alcohol near bedtime and sedatives can relax airway muscles and worsen OSA. High altitude may drive hypoxia and erythrocytosis; smokers have additive risks. Addressing these factors can simplify TRT management.
  • Age and comorbidity: Late-onset hypogonadism often overlaps with OSA, visceral adiposity, insulin resistance, and hypertension. Multifaceted care tends to outperform single-issue fixes.

How Taurus Meds Approaches TRT in the Context of Sleep Apnea

  • We screen for OSA risk before and after starting TRT and coordinate with sleep specialists when a formal evaluation is appropriate.
  • We support CPAP-first sequencing when OSA is moderate to severe, then reassess hormonal status and symptoms.
  • We aim for physiologic testosterone targets and use monitoring plans that include hematocrit, blood pressure, and symptom check-ins.
  • When lab results or symptoms shift, we adjust dosing or timing and collaborate with your sleep team to keep therapy safe and effective.

The goal is not just “higher T,” but better health, energy, and sexual function—with sleep and cardiometabolic risk in view.

What We Still Don’t Know (Yet)

  • The best sequencing strategy for mild OSA with borderline low T (e.g., simultaneous CPAP and low-dose TRT vs. stepwise)
  • How different TRT formulations and dosing schedules affect apnea metrics over years, not months
  • Long-term rates of erythrocytosis and cardiovascular outcomes in men with OSA on TRT
  • The full impact of modern weight-loss therapies on the OSA–hypogonadism axis

As new data emerge, recommendations may evolve from caution-based to more individualized risk profiles.

Conclusion

TRT and sleep apnea intersect in ways that can either help or hinder your goals. Untreated OSA can depress testosterone and mimic hypogonadal symptoms, and TRT—especially at higher peaks—may aggravate sleep-disordered breathing in some men. The safest path for many is straightforward: identify and treat OSA first, then personalize TRT if hypogonadism persists, with vigilant monitoring of hematocrit, blood pressure, and sleep quality. With this approach, many men experience meaningful gains in energy, sexual function, and overall well-being—without losing ground on sleep or safety.

Disclaimer

This article is for educational purposes only and is not a substitute for personalized medical advice. Do not start, stop, or change any medication or device (including CPAP) without consulting a qualified clinician.

Sources

Oral TRT Prolactin Monitoring Under the Tlando Label

Posted on by Taurus

Oral TRT Prolactin Monitoring Under the Tlando Label

Estimated reading time: 8 minutes

Key takeaways

  • The FDA-approved Tlando label instructs clinicians to check serum prolactin before initiation and again 3–4 months after starting; discontinue if prolactin remains elevated after starting.
  • Short-term data show occasional, modest prolactin rises (about 6.3% of participants; mean ~+7.0 ng/mL in a 24-day study), prompting label-level monitoring guidance.
  • Injectable TRT products generally do not include a similar prolactin monitoring requirement in their labels.
  • Monitoring still centers on testosterone levels, hematocrit, blood pressure, and prostate parameters; prolactin is a formulation-specific add-on for Tlando.
  • Plan baseline and 3–4 month labs with your clinician to align therapy and follow-up with label guidance.

Table of contents

  1. Why Prolactin Is Entering the TRT Conversation Now
  2. What the FDA Required After Tlando’s Approval
  3. What the Clinical Data Show So Far
  4. How Monitoring Differs for Oral TRT vs. Injectables
  5. Practical Implications for Patients Considering Oral TRT
  6. Open Questions: HPA Axis and Long-Term Safety
  7. How Taurus Meds Thinks About “Testosterone Prolactin Levels” in Care Plans
  8. Conclusion

TRT Monitoring Protocols for Prolactin in Oral Formulations: What Tlando’s FDA Label Means for Patients

Oral testosterone undecanoate has changed how some men approach testosterone replacement therapy (TRT). But Tlando (oral testosterone undecanoate), approved by the FDA in 2022, arrives with a unique monitoring note that often surprises patients and clinicians alike: check serum prolactin before starting and again 3–4 months after initiation, with discontinuation advised if prolactin remains elevated. That language appears in the FDA-approved prescribing information and is not emphasized in most injectable TRT protocols. This article unpacks what that means in practice, how we got here, and what open questions remain for oral TRT users.

Why Prolactin Is Entering the TRT Conversation Now

Prolactin is a pituitary hormone. Outside of specific clinical contexts, it is not routinely emphasized in standard TRT monitoring. That changed for oral testosterone undecanoate with Tlando, whose FDA label explicitly instructs clinicians to check serum prolactin levels before starting therapy and again after 3–4 months of treatment, and to discontinue if levels remain elevated after initiation.

This labeling followed clinical trial findings that suggested an inconsistent but real signal for prolactin increases during short-term exposure. The FDA addressed the signal in the Warnings and Precautions section of Tlando’s label and retained that language in a subsequent 2025 label update. This is a formulation-specific requirement, not a universal standard across all TRT modalities. For men exploring oral TRT, that means prolactin is a practical monitoring step that may influence whether you remain on a given regimen.

What the FDA Required After Tlando’s Approval

When Tlando (NDA 208088) was approved in 2022, the FDA mandated several postmarketing studies under Section 505(o)(3) of the FDCA. Among those were studies related to potential hypothalamic–pituitary–adrenal (HPA) axis effects, reflecting the agency’s interest in endocrine consequences beyond serum testosterone.

At the same time, the FDA’s review flagged increased prolactin as a safety signal. Rather than requiring a separate postmarketing study solely devoted to prolactin, the agency incorporated a clear action into the label: screen prolactin before initiation, reassess 3–4 months into therapy, and discontinue if it remains elevated after starting. A 2025 label update retained this approach, providing a defined pathway for surveillance and action while longer-term data mature.

What the Clinical Data Show So Far

  • In a 24-day clinical study of Tlando, 6.3% (6 of 95) of participants experienced increases in serum prolactin, with a mean change of approximately +7.0 ng/mL from baseline.
  • A longer 4-month study did not reassess prolactin after screening, so longitudinal changes beyond the initial period are not well characterized in the pivotal data.
  • The FDA considered the prolactin findings inconsistent but noteworthy enough to address through labeling.

Two caveats matter for interpretation:

  • The label does not define a numeric threshold for “elevated” prolactin. Reference intervals vary across labs, so the decision to stop therapy hinges on clinician judgment and patient-specific context.
  • The label cautions against use in patients with prolactin-dependent tumors, underscoring the potential clinical weight of prolactin changes in certain conditions.

Bottom line: the data suggest occasional, modest increases in prolactin with Tlando in the short term, with an FDA-mandated monitoring protocol. The clinical significance of small, asymptomatic increases remains uncertain, and longer-term data are still developing.

How Monitoring Differs for Oral TRT vs. Injectables

Most TRT programs, whether topical or injectable, focus on:

  • Achieving physiologic testosterone levels and rechecking after initiation or dose changes
  • Watching hematocrit/hemoglobin to reduce the risk of erythrocytosis
  • Checking blood pressure and cardiovascular risk factors
  • Assessing prostate health parameters as clinically indicated

For Tlando specifically, the label highlights:

  • Serum testosterone: measure about 3–4 weeks after starting to ensure levels fall within the target range (the Tlando label uses a window of approximately 300–1080 ng/dL).
  • Serum prolactin: check prior to initiation and again 3–4 months into therapy; discontinuation is advised if prolactin remains elevated after starting.

Injectable testosterone products generally do not include an FDA-labeled requirement to monitor prolactin in the same way. That difference does not make injectables universally simpler or risk-free—it just means prolactin is not a labeled focus. Regardless of modality, ongoing assessment of hematocrit and cardiovascular risk is core to responsible TRT care.

Practical Implications for Patients Considering Oral TRT

  • Baseline labs with intention: If prolactin will inform whether you start or continue Tlando, plan the test before initiation. Ask how “elevated” will be defined within your lab’s reference interval and clinical context.
  • The 3–4 month checkpoint: Put a date on the calendar for both testosterone and prolactin checks. Clarify in advance what will happen if prolactin is elevated—repeat testing, additional evaluation, a pause, or a switch in modality.
  • Interpretation matters: Small increases may be clinically irrelevant; persistent or marked elevations may prompt action. With no absolute cut-off in the label, real-world decisions rely on clinician judgment and your overall health picture.
  • The monitoring trade-off: Some patients prefer oral formulations to avoid injections; others prioritize fewer lab-specific requirements. Understanding how prolactin fits into follow-up can clarify your choice.
  • Dosing context: Tlando is administered 225 mg twice daily with food. This can influence adherence and lab timing; discuss how and when to draw labs relative to dosing and meals.

Open Questions: HPA Axis and Long-Term Safety

The FDA’s postmarketing requirements for Tlando include studies examining potential HPA axis effects. While prolactin is related to the pituitary, the HPA axis covers a broader endocrine system. These commitments reflect interest in endocrine ripple effects of oral testosterone undecanoate beyond testosterone itself.

Key uncertainties to watch:

  • Do oral formulations uniquely affect prolactin compared with injectables?
  • What is the long-term trajectory of prolactin changes beyond a few months of therapy?
  • Which patients, if any, are more prone to sustained prolactin elevations on oral TU?
  • Do elevations remain subclinical or translate into meaningful symptoms or risks in specific subgroups?

As evidence from real-world use and postmarketing work grows, labels could evolve. For now, the prolactin language remains in place and provides concrete guidance for early monitoring.

How Taurus Meds Thinks About “Testosterone Prolactin Levels” in Care Plans

In practice, the label’s direction translates into a simple, time-bound check for oral TU users: screen prolactin at baseline, and reassess after 3–4 months. That’s a manageable addition to the standard testosterone, hematocrit, blood pressure, and prostate monitoring you and your clinician might already be doing.

For men deciding between oral and injectable TRT, the difference is more about coordination than complexity. If you value oral dosing, plan for the extra prolactin data point. If minimizing lab variability is your priority, injectables may feel more familiar. Either path benefits from a structured lab schedule and clear follow-up conversations.

Taurus Meds supports patients in building these schedules, aligning tests with label guidance, and coordinating with clinicians so that therapy decisions are made with the right information at the right time.

Conclusion

Oral testosterone undecanoate via Tlando introduced a specific, FDA-labeled expectation: monitor serum prolactin before starting, then again 3–4 months into therapy, and discontinue if levels remain elevated after initiation. The evidence behind that instruction is limited and somewhat inconsistent, but the label treats the signal seriously enough to structure care around it.

Injectable TRT modalities do not share this prolactin requirement, which may factor into treatment selection for some men. Regardless of the route, a careful monitoring plan remains essential: track testosterone levels, hematocrit, cardiovascular parameters, and clinician-directed prostate assessments. The right regimen is the one that aligns with your health status, preferences, and ability to engage with monitoring.

As postmarketing studies mature—particularly those related to the HPA axis—expect the evidence base to grow. For now, the safest path is to follow the label, recognize uncertainty where it exists, and make shared decisions with your care team.

Disclaimer

This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication or monitoring plan without consulting a qualified healthcare professional.

Sources

TRT in Older Obese Men LITROS Trial Findings on Function and Body Composition

Posted on by Taurus

TRT in Older Obese Men LITROS Trial Findings on Function and Body Composition

Estimated reading time: 9 minutes

Key takeaways

  • In a 26-week program of intensive diet and supervised exercise, TRT did not add to overall physical performance test scores but helped preserve lean mass and hip BMD.
  • TRT modestly improved VO₂peak and showed signals for cognitive benefit; gains tracked with changes in fitness, strength, and hormones.
  • Metabolomic data suggest TRT restores muscle glycolytic capacity, supporting metabolic flexibility during weight loss.
  • Both TRT and placebo groups improved triglycerides and metabolic syndrome scores with weight loss; TRT showed additional metabolic flexibility signals.
  • Findings are from a small, frail cohort over 26 weeks; long-term safety and durability remain uncertain.

Table of contents

  1. The LITROS Trial at a Glance
  2. What Did TRT Add Beyond Lifestyle?
  3. Mechanism: Restoring Glycolysis and Metabolic Flexibility
  4. Cognitive Outcomes
  5. Why No Extra Boost in Physical Performance Tests?
  6. Safety and Limitations
  7. Practical Considerations
  8. Who Might Be a Candidate?
  9. Open Questions
  10. Bottom Line

Older men with obesity and low testosterone often face a dilemma: how to lose weight without accelerating muscle and bone loss. The LITROS trial (NCT02367105) tested a pragmatic idea—pair medically guided weight loss and supervised exercise with testosterone replacement therapy (TRT)—to see whether TRT could protect lean mass and bone while improving other aging-related outcomes. The results are nuanced and clinically relevant for older obese men considering TRT as part of a structured program.

The LITROS Trial at a Glance

  • Who: 83 men aged 65+ with obesity (BMI ≥30 kg/m²), low testosterone (<10.4 nmol/L), and reduced function (Physical Performance Test ≤31)—a frail population.
  • Design: 26-week, double-blind, placebo-controlled trial of testosterone vs. placebo. All participants received intensive lifestyle intervention: diet targeting ~10% weight loss plus supervised aerobic and resistance training.
  • Goal: Determine whether adding TRT to optimized lifestyle meaningfully improves function, body composition, bone health, metabolism, and cognition in frail, hypogonadal, obese older men.

This design isolates what TRT adds when lifestyle is already optimized—mirroring real-world goals for losing weight without worsening sarcopenia or bone loss.

What Did TRT Add Beyond Lifestyle?

Lifestyle change drove clear improvements in both groups. The incremental effects of TRT were selective but meaningful.

  • Lean body mass: TRT attenuated loss (about −2% vs. −3% with placebo; P = 0.01), reducing sarcopenia risk during weight loss.
  • Thigh muscle volume: Smaller decline with TRT (about −2% vs. −4%; P = 0.04), potentially preserving strength reserve.
  • Hip bone mineral density: Shift from loss to preservation (+0.5% with TRT vs. −1.1% with placebo; P = 0.003).
  • Aerobic capacity (VO₂peak): Both groups improved; TRT produced a greater increase—an additive cardiorespiratory fitness effect.
  • Physical Performance Test (PPT): Similar improvements in both groups; no added composite functional gain with TRT at 26 weeks.
  • Metabolism: Triglycerides and metabolic syndrome scores improved with weight loss in both groups; TRT showed additional signals of metabolic flexibility.

Clinically, TRT functioned as a protective adjunct during intensive weight loss and training—helping keep muscle and bone “on board” while nudging aerobic conditioning.

Mechanism: Restoring Glycolysis and Metabolic Flexibility

A metabolomic substudy of LITROS found that TRT appeared to reprogram skeletal muscle toward greater glycolytic capacity—the ability to quickly generate energy from glucose—crucial during caloric restriction and training.

  • Glycolysis was the primary pathway consistently restored at six months in the TRT group.
  • This aligns with preserved lean mass and thigh muscle volume and may help explain the VO₂peak advantage.
  • The data suggest enhanced metabolic flexibility with TRT, supporting more adaptive responses to diet and exercise.

These insights clarify how TRT may counter weight loss–induced catabolism; whether adaptations persist after stopping TRT is unknown.

Cognitive Outcomes

  • Global cognition improved more with TRT than with lifestyle alone.
  • Predictors of cognitive gains included changes in VO₂peak, muscle strength, total testosterone, and luteinizing hormone—suggesting brain benefits tracked with systemic fitness and hormonal changes.

Cognitive outcomes were secondary and not powered for domain-specific effects after multiple-comparison adjustment, but the signal toward benefit in a structured program is noteworthy.

Why No Extra Boost in Physical Performance Tests?

  • Strong lifestyle effect: Both groups lost ~9% body weight and improved function; short-term floor/ceiling effects can obscure incremental gains.
  • Composite metric limits: PPT aggregates domains (walking, balance, transfers) that may respond more to practice or weight loss than to anabolic signals over six months.
  • Time horizon: Mechanistic advantages (glycolysis, lean mass, bone) may translate to longer-term resilience not captured at 26 weeks.

Safety and Limitations

  • Short duration, small size: 26 weeks; n=83. Durability after discontinuation is unknown.
  • Specific population: Predominantly male Veterans, 65+, obese, hypogonadal, frail—generalizability is limited.
  • Context matters: All participants pursued significant caloric restriction and supervised exercise; effects outside this setting are unclear.
  • Hard outcomes unassessed: Not powered for cardiovascular events, fractures, or prostate outcomes.
  • Mechanistic subset: Muscle metabolomics were performed in a subset; representativeness is uncertain.

Regulatory note: In the U.S., TRT approvals rely on achieving physiologic testosterone levels, not on demonstrated outcome improvements. LITROS provides investigator-driven outcome data for a specific population.

Practical Considerations

  • Lifestyle is foundational: Diet and supervised training drove most functional gains; view TRT (when indicated) as an adjunct to protect lean mass and bone and support aerobic capacity.
  • Expect selective benefits: Don’t expect large added improvements in everyday performance tests over six months; clearest TRT effects were on lean/thigh muscle, hip BMD, and modest VO₂peak gains.
  • Cognition tracks fitness: Cognitive improvements moved with aerobic fitness, strength, and normalized hormones.
  • Monitoring is essential: TRT requires labs and follow-up; optimal dosing and long-term risk–benefit remain open questions.
  • Individual variability: Responses differ; metabolomic data hint at potential “responders,” but prediction is not yet possible.
  • Time horizon: Six months is short in geriatrics; decisions should align with long-term goals and comorbidities.

Who Might Be a Candidate?

  • Men aged 65+ with confirmed clinical hypogonadism
  • Obesity and functional limitations consistent with frailty
  • Capacity and motivation for a structured weight loss and supervised exercise program for at least six months

Findings may not translate to non-frail older men, those unable to engage in structured lifestyle programs, or younger populations. Shared decision-making with a qualified clinician is essential.

Open Questions

  • Durability: Do muscle, bone, metabolic, and cognitive benefits persist beyond six months or require ongoing therapy/training?
  • Safety at scale: What are long-term cardiovascular, prostate, and thromboembolic risks/benefits in this high-risk population?
  • Dose optimization: Could lower doses achieve similar protection with fewer risks?
  • Generalizability: Would results replicate in more diverse, non-Veteran, or non-frail cohorts?
  • Mechanistic markers: Can glycolytic “responders” be identified to personalize therapy?
  • Value: Is adjunctive TRT cost-effective relative to monitoring and medication burden?

Bottom Line

For older obese men pursuing intensive, medically guided weight loss and supervised training, LITROS offers a measured message. Lifestyle change is the engine of improved physical performance. Adding TRT did not further raise composite performance scores over six months—but it did preserve lean muscle and hip bone density, modestly improved VO₂peak, supported metabolic flexibility via renewed glycolysis, and showed signals for cognitive benefit. These selective effects are relevant for frail seniors aiming to lose weight without sacrificing muscle and bone.

The data are promising yet preliminary: the trial was short, small, and not powered for hard safety outcomes. If you fit the LITROS profile, discuss goals, risks, and the commitment required for structured lifestyle change with your clinician.

Disclaimer

This article is for informational purposes only and is not medical advice. It does not diagnose, treat, or recommend any therapy. Decisions about testosterone therapy should be made with a qualified healthcare professional who can assess your individual situation.

Sources

Oral Testosterone Undecanoate Shows No Liver Harm Over Two Years

Posted on by Taurus

Oral Testosterone Undecanoate Shows No Liver Harm Over Two Years

Estimated reading time: 8 minutes

Key takeaways

  • Two-year follow-up of oral testosterone undecanoate (TU; Jatenzo) in hypogonadal men showed no clinically meaningful liver toxicity and stable liver function tests.
  • Safety signals (PSA, hematocrit, HDL reduction, and modest blood pressure rise) were consistent with other TRT options like injections and gels.
  • TU is absorbed via the lymphatic system, avoiding first-pass hepatic metabolism that contributed to liver risks with older oral androgens.
  • Evidence is reassuring but limited by open-label design, small sample size (n=86 at 2 years), and follow-up capped at two years.
  • Monitoring for hematocrit, PSA, blood pressure, and lipids remains standard for men on any TRT regimen.

Table of contents

  1. Why “Oral Testosterone” Once Meant Liver Worries
  2. What Is Oral Testosterone Undecanoate (Jatenzo) and How It Differs
  3. The 2-Year Safety Data at a Glance
  4. What This Means for “Oral TRT Liver Damage”
  5. Other Safety Considerations: What to Watch
  6. Practical Implications for Patients Considering Jatenzo
  7. Limitations of the Evidence and Open Questions
  8. How Oral TU Fits Among TRT Options
  9. Conclusion

Oral TU Liver Safety: 2-Year Data Confirms No Hepatotoxicity vs Older Forms

Oral testosterone therapy has long carried a stigma around liver risk, largely due to experiences with older formulations. The recent 2-year data on oral testosterone undecanoate (TU; brand name Jatenzo) offers a very different picture: maintenance of normal testosterone levels with no evidence of hepatotoxicity in hypogonadal men. Below we break down what changed, what the evidence shows, and what it means if you’re weighing oral TRT against injections or gels.

Why “Oral Testosterone” Once Meant Liver Worries

For years, “oral testosterone” was practically synonymous with “liver risk.” That reputation was earned by alkylated oral androgens such as methyltestosterone, which were historically linked to hepatotoxicity. Those older molecules undergo significant first-pass metabolism in the liver and have been associated with adverse hepatic outcomes.

Oral testosterone undecanoate (TU) is a fundamentally different approach. Rather than pushing a molecule through the liver to achieve active levels, TU leverages lymphatic absorption to bypass first-pass hepatic metabolism. The clinical question has been whether this mechanism translates into real-world liver safety. Two-year data now provide a more confident answer.

What Is Oral Testosterone Undecanoate (Jatenzo) and How It Differs

  • FDA timeline: Jatenzo (oral TU) received FDA approval in March 2019 and became commercially available in early 2020.
  • Absorption: TU is delivered as an ester that is preferentially absorbed via the intestinal lymphatic system, aiming to reduce first-pass liver exposure.
  • Clinical positioning: It offers a needle-free option that avoids the transfer risk of gels. For many men who dislike injections or find transdermal adherence challenging, oral TU provides a practical alternative.

Importantly for men worried about oral TRT liver damage, the clinical trials and the two-year extension study did not show clinically meaningful changes in liver function tests (LFTs).

The 2-Year Safety Data at a Glance

A 2-year open-label extension followed 86 hypogonadal men who continued on oral TU after an initial year of therapy. The results are notable for both efficacy and safety:

  • Testosterone levels: Men maintained eugonadal (normal) serum testosterone throughout the study period.
  • Liver function: No clinically significant changes were observed in ALT, AST, alkaline phosphatase, or bilirubin over the 2-year period. One participant had a transient ALT elevation to more than 4 times the upper limit of normal around Day 270, which normalized by Day 290 without ongoing liver issues.
  • Prostate and hematologic signals: Small, statistically significant increases in prostate-specific antigen (PSA) and hematocrit were observed—changes consistent with what’s seen across injectable and transdermal TRT.
  • Lipids and blood pressure: Minimal LDL impact was reported, with a decrease in HDL cholesterol that is typical of TRT. Average systolic blood pressure rose modestly (on the order of a few millimeters of mercury).
  • Overall: The safety profile of oral TU tracked closely with non-oral TRT options and did not show the hepatotoxicity historically associated with older oral androgens.

These findings echo earlier trial data showing stable LFTs with oral TU and support the idea that TU’s lymphatic absorption avoids the liver strain that prompted concern with prior oral agents.

What This Means for “Oral TRT Liver Damage”

If you’re searching “oral TRT liver damage,” you’re likely trying to separate past concerns from current options. The key takeaway is that oral TU (Jatenzo) does not behave like older alkylated oral androgens with respect to the liver. Over two years of follow-up in hypogonadal men:

  • No signal of clinically meaningful hepatotoxicity was seen.
  • Routine lab monitoring did not show problematic trends in liver enzymes or bilirubin.
  • A single, short-lived ALT spike did not translate to broader safety concerns.

While any medication can affect individuals differently, the best available clinical evidence suggests that oral TU’s design—bypassing first-pass hepatic metabolism—largely decouples modern oral TRT from the historical liver damage narrative.

Other Safety Considerations: What to Watch

Oral TU’s liver profile is encouraging, but TRT monitoring remains important regardless of delivery method. The signals below are expected class effects and are reflected in oral TU data and labeling:

  • Hematocrit: TRT can increase red blood cell mass. Clinicians routinely track hematocrit and may adjust or pause therapy if levels become too high.
  • PSA and prostate health: Small increases in PSA can occur; monitoring and clinical context matter, especially for men with known prostate risks.
  • Blood pressure: Average systolic blood pressure increases of roughly 3–6 mmHg have been observed. Men with existing hypertension should have blood pressure routinely assessed.
  • Lipids: Some reduction in HDL is typical with TRT.
  • Indication: Like other testosterone products, oral TU is indicated for men with confirmed hypogonadism; it is not approved for age-related testosterone decline without a clear deficiency diagnosis.

These are not reasons to avoid therapy outright; they are part of the risk-benefit calculus that clinicians use to guide safe, individualized TRT.

Practical Implications for Patients Considering Jatenzo

  • Convenience and adherence: Oral TU offers a needle-free route and avoids gel transfer risk to partners or children. For some men, daily oral dosing improves adherence; others may prefer less frequent injection schedules.
  • Monitoring cadence: As with any TRT, expect baseline labs and periodic follow-up for hematocrit, PSA, lipids, and blood pressure. The 2-year data support that these parameters typically move in the same direction as with non-oral TRT.
  • Liver reassurance: For men specifically concerned about oral testosterone and the liver, the available two-year evidence is reassuring and materially different from experiences with older oral agents.
  • Individual variability: Dosing and response can vary. Maintaining eugonadal levels is the goal; clinicians may adjust dosing based on serum testosterone and side-effect profile.
  • Lifestyle and comorbidities: Pre-existing cardiovascular risk, sleep apnea, or prostate history may shape the choice and monitoring plan. The absence of hepatotoxicity does not eliminate broader TRT considerations.
  • Access and support: Coordinated care—including lab scheduling, medication management, and clear follow-up plans—helps sustain both efficacy and safety over time. At Taurus Meds, we focus on providing structured support so patients and clinicians can track progress and make informed decisions.

Limitations of the Evidence and Open Questions

The two-year data on Jatenzo are meaningful, but not definitive for all questions men might have about long-term safety:

  • Study design and size: The extension was open-label and industry-supported, with 86 men completing two years. While informative, it’s not a large, blinded outcomes trial.
  • Duration: Data beyond two years are limited. Longer follow-up will be important for understanding cardiovascular and prostate outcomes over time.
  • Comparative effectiveness: Head-to-head trials versus other modern TRT formulations could clarify differences in adherence, metabolic effects, and patient-reported outcomes.
  • Real-world use: Adherence patterns and variability in absorption outside of trial settings merit ongoing study, including how different oral TU products perform across diverse patient populations.

For now, the best reading of the evidence is that oral TU delivers the expected benefits of TRT with a safety profile consistent with non-oral options—and without the liver toxicity shadow that accompanied earlier oral androgens.

How Oral TU Fits Among TRT Options

  • Injections: Offer predictable testosterone exposure with dosing every 1–2 weeks (or longer with some esters). Some men prefer fewer dosing events; others dislike needles or experience peak–trough swings.
  • Transdermals: Avoid needles and allow daily dosing, but require skin precautions to prevent transfer and may cause local irritation.
  • Oral TU: Provides daily oral dosing without first-pass liver metabolism. The two-year data support its liver safety and expected TRT class effects.

The “right” option depends on confirmation of hypogonadism, personal preferences, lifestyle, tolerance, and ongoing lab and clinical findings. It’s reasonable to consider oral TU if you want a needle-free route and are reassured by the emerging liver safety profile.

Conclusion

Oral TU (Jatenzo) represents a significant shift in how we think about oral testosterone. The two-year extension data in hypogonadal men show no evidence of hepatotoxicity, with liver function remaining stable and overall safety tracking closely with injections and gels. While monitoring for hematocrit, PSA, blood pressure, and lipids remains standard, the long-standing association between “oral TRT” and liver damage does not reflect what we see with TU.

As with all TRT decisions, individualized assessment and thoughtful follow-up matter. The current evidence offers men a practical, needle-free option that appears to sidestep the liver risks of older oral androgens—an important development for patient choice and comfort.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any questions you have regarding a medical condition or therapy.

Sources

TRT and Prolactin Evidence from Oral Testosterone Approvals

Posted on by Taurus

TRT and Prolactin Evidence from Oral Testosterone Approvals

Estimated reading time: 8 minutes

FDA materials for Tlando note increased prolactin without consistent human data. Learn which labs to prioritize on TRT and when prolactin testing is warranted.

Key takeaways

  • FDA reviewers flagged increased serum prolactin during Tlando development as an “inconsistent finding,” and it is not a routine monitoring requirement in final labeling.
  • The prolactin signal has not been consistently observed across other TRT products, and human trial data do not quantify magnitude or frequency.
  • Plausible mechanisms (e.g., HPA axis effects in animals, estradiol aromatization) remain unproven as clinically meaningful drivers in routine care.
  • Prioritize standard TRT labs (testosterone, hematocrit, blood pressure, PSA). Add prolactin selectively for symptom‑guided scenarios.
  • Open questions remain about whether oral TRT uniquely affects prolactin and what any changes mean for outcomes.

Table of contents

  1. Why prolactin came up in oral TRT reviews
  2. What “inconsistent” really means for patients
  3. Potential biology: why might TRT influence prolactin?
  4. Oral vs. injectable TRT: is prolactin different?
  5. Practical monitoring: what to prioritize and when to consider prolactin
  6. How to think about a mild prolactin bump on TRT
  7. What we still don’t know
  8. A note on clinical relevance
  9. Where Taurus Meds fits
  10. Conclusion

Why prolactin came up in oral TRT reviews

Tlando, an oral testosterone undecanoate formulation (NDA 208088), underwent multiple FDA review cycles spanning several years. During those reviews, regulators highlighted several safety observations, including:

  • Increased blood pressure
  • An average hematocrit rise (about 3.2% over 110 days in one key study)
  • Potential HPA axis effects (evidence of adrenal cortical changes in animals)
  • An inconsistent signal of increased serum prolactin

That “inconsistent” label matters. It means elevations weren’t reliably demonstrated across studies or did not show clear dose-response, incidence, or clinical outcomes. Ultimately, while postmarketing monitoring was discussed across several domains, prolactin was not included as a required routine lab in the final Tlando labeling.

By contrast, standard TRT warnings and monitoring remain focused on:

  • Hematocrit/erythrocytosis
  • Blood pressure
  • Suppression of the pituitary‑testicular axis (fertility/testicular effects)
  • PSA and prostate considerations

Notably, prolactin does not appear as a general monitoring requirement in long‑standing injectable testosterone labels or in the Jatenzo (oral TU) review, underscoring that it isn’t an established safety endpoint across the class.

Sources: FDA summary review for Tlando; injectable testosterone label; Jatenzo medical review; FDA TRT guidance.

What “inconsistent” really means for patients

“Inconsistent” does not necessarily mean “unimportant”—it means the evidence is too patchy for firm regulatory conclusions. For TRT prolactin questions, the limitations include:

  • No standardized reporting of prolactin incidence or magnitude in human trials.
  • Short trial durations (e.g., around 110 days for a pivotal safety dataset).
  • A development focus on pharmacokinetics and blood pressure rather than prolactin.
  • Lack of consistent replication across products and studies.

Because of these gaps, prolactin is not a routine monitoring target in product labels or in general TRT guidance. Still, individual patients may benefit from case‑by‑case testing, especially if symptoms suggest prolactin involvement.

Potential biology: why might TRT influence prolactin?

A few plausible pathways are discussed in regulatory and scientific contexts, none proven as a primary driver in typical TRT care:

  • HPA axis interactions: Animal toxicology noted adrenal cortical changes at exposures relevant to testosterone therapy. Translating animal adrenal findings into human prolactin changes is speculative; the relevance in standard human dosing remains uncertain.
  • Aromatization to estradiol: Testosterone can convert to estradiol, which may influence prolactin in some contexts. If estradiol rises (for example, in patients who aromatize more readily), it might indirectly affect prolactin. Evidence connecting typical TRT dosing to clinically meaningful prolactin elevations remains limited.
  • Pituitary feedback: While injectable labels emphasize suppression of the pituitary‑testicular axis, routine prolactin shifts have not been established as a class effect.

Bottom line: theoretical mechanisms exist, but human data are thin, and clinical significance appears low for most patients.

Oral vs. injectable TRT: is prolactin different?

So far, the suggestion of increased prolactin has surfaced most clearly in the FDA’s Tlando materials—without consistent confirmation in other approvals (e.g., Jatenzo, Xyosted). That could reflect differences in study design, populations, or statistical noise rather than a true formulation effect.

It remains an open question whether oral TRT uniquely affects prolactin compared with injectables or topicals. Regulatory documents do not establish a causal relationship or a consistent pattern. Without robust human data, it’s prudent to view any prolactin signal as a product‑specific observation that has not yet generalized to the TRT category.

Practical monitoring: what to prioritize and when to consider prolactin

For most patients on TRT—oral or otherwise—the standard monitoring priorities remain:

  • Testosterone levels in target range per prescriber guidance
  • Hematocrit/hemoglobin to watch for erythrocytosis
  • Blood pressure
  • PSA and prostate assessment consistent with age and risk
  • Assessment for edema, acne, mood or sleep changes, and other dose‑related effects

When to consider adding prolactin:

  • New or worsening gynecomastia not explained by other factors
  • Persistent sexual dysfunction (e.g., reduced libido, anorgasmia) despite adequate testosterone exposure
  • Nipple discharge or breast tenderness out of proportion to expected aromatization effects
  • Refractory headaches or visual symptoms that necessitate broader endocrine evaluation
  • Clinical scenarios where the prescriber already plans to check estradiol, thyroid function, or pituitary hormones and wants a fuller pituitary profile

This selective approach accommodates the FDA’s “inconsistent” signal without over-testing. It also aligns with how clinicians often tailor labs to symptoms, comorbidities, and the specific formulation used.

How to think about a mild prolactin bump on TRT

If a prolactin elevation is found incidentally:

  • Confirm it: Single measurements can be misleading. Non‑TRT factors (stress, time of day, certain medications) can affect prolactin.
  • Correlate with symptoms: Modest, asymptomatic elevations may not require immediate changes. Significant symptoms should trigger a fuller work‑up per clinician judgment.
  • Consider other labs: Some prescribers evaluate estradiol in symptomatic “high‑aromatizers,” as well as thyroid function if indicated, to contextualize prolactin findings.
  • Revisit formulation or dose: If concerns persist and are plausibly linked to oral pharmacokinetics or peaks, a switch to a non‑oral formulation may be discussed.

Because the FDA materials do not quantify the prolactin signal or link it to outcomes, management remains individualized and anchored to broader clinical context rather than any single lab value.

What we still don’t know

  • Does oral testosterone undecanoate genuinely increase prolactin more than injectable or transdermal options?
  • If elevations occur, how often, how much, and at what threshold do symptoms appear?
  • Are observed animal HPA findings relevant to typical human dosing and duration?
  • Do estradiol levels or dose intensity explain inter‑individual differences?
  • Will ongoing or future postmarketing studies clarify whether prolactin monitoring should be standardized for oral TRT?

Until these gaps close, routine prolactin testing for all TRT patients is not supported by labeling or guidance. The stronger evidence continues to support monitoring hematocrit, blood pressure, and other established safety endpoints.

A note on clinical relevance

For men on TRT, the primary concerns remain consistent: achieving physiologic testosterone exposure while minimizing risks like erythrocytosis and blood pressure changes. The current evidence suggests that clinically meaningful prolactin problems linked directly to TRT are uncommon. That said, a symptom‑led approach to prolactin testing can help identify rare but important issues without burdening every patient with added labs.

Where Taurus Meds fits

At Taurus Meds, we track regulatory updates closely and support pragmatic, evidence‑based monitoring plans. If you’re initiating or already on oral TRT and have symptoms that raise prolactin questions, discuss them with your prescribing clinician. Thoughtful lab selection—focused on the highest‑value tests for your situation—can keep treatment effective and safe without unnecessary complexity.

Conclusion

TRT prolactin remains a nuanced topic. The FDA’s Tlando review flagged increased serum prolactin as an inconsistent finding, and animal data raise theoretical HPA considerations. Yet no clear, reproducible human signal has prompted routine prolactin monitoring in approvals or class guidance. For now, the most practical course is to continue standard TRT monitoring and reserve prolactin testing for patients with suggestive symptoms or tailored clinical reasons—especially on oral regimens—while we await more definitive postmarketing data.

Disclaimer

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about diagnosis, lab interpretation, or treatment decisions.

Sources

TRT and Blood Clot Risk FDA Warnings and Real-World Incidence

Posted on by Taurus

TRT and Blood Clot Risk FDA Warnings and Real-World Incidence

Estimated reading time: 9 minutes

Key takeaways

  • The FDA requires a class-wide VTE warning on testosterone labels; clinicians should discontinue therapy if VTE is suspected.
  • In 2025, labels dropped the boxed MACE warning, added blood pressure effects, and retained the VTE warning.
  • Real-world VTE incidence specifically attributable to TRT remains unclear; post-marketing data signal risk but don’t quantify it.
  • Men with prior clots, thrombophilia, or significant comorbidities may need enhanced risk assessment and shared decision-making.
  • Monitoring hematocrit (polycythemia) and blood pressure is central to safe TRT use.

Table of contents

  1. Overview
  2. Why the FDA warns about VTE on testosterone labels
  3. What changed in 2025: FDA label update in context
  4. Post-marketing reports: strengths and limits
  5. What clinical trials do—and don’t—tell us
  6. Real-world incidence: why a clear number is elusive
  7. Which patients may face higher VTE risk?
  8. Practical implications if you’re considering or using TRT
  9. Recognizing possible DVT/PE symptoms
  10. Open research questions
  11. How Taurus Meds approaches safety
  12. Conclusion
  13. Disclaimer
  14. Sources

Overview

For men considering testosterone replacement therapy (TRT), questions about blood clots—deep vein thrombosis (DVT) and pulmonary embolism (PE)—are common and reasonable. The U.S. Food and Drug Administration (FDA) requires a venous thromboembolism (VTE) warning on testosterone product labels based on post-marketing reports, but published real-world incidence rates remain limited. This article reviews what the FDA labels actually say, how recent updates affect clinical context, and what practical implications follow for patients—especially those with a history of clots or known thrombophilia.

Why the FDA warns about VTE on testosterone labels

The 2022 prescribing information for testosterone cypionate includes a dedicated warning about venous thromboembolism (DVT/PE). This stems from post-marketing reports where users developed blood clots, sometimes not explained by polycythemia (an elevated red blood cell mass that can increase clot risk). The label instructs clinicians to consider VTE in patients with suggestive symptoms and to discontinue testosterone if VTE is suspected.

This class-wide action follows an FDA decision in 2014 to update all testosterone products with explicit VTE warnings. The FDA’s rationale drew on spontaneously reported events rather than a single definitive clinical trial signal. In other words, regulators saw enough real-world cases to warn prescribers and patients, even though the exact rate remains uncertain.

  • TRT VTE risk is explicitly acknowledged on labels.
  • The warning applies across product types as a class effect.
  • It reflects a safety signal observed after marketing, not necessarily a quantified risk from randomized trials.

What changed in 2025: FDA label update in context

On February 28, 2025, the FDA updated labeling for testosterone products informed by newer data, including the TRAVERSE trial (results reported in 2023). Three changes are most relevant for men researching TRT blood clots:

  • The boxed warning related to MACE was removed, as contemporary evidence did not support a boxed warning for broad cardiovascular events.
  • New labeling clarifies that testosterone can increase blood pressure, drawing on ambulatory blood pressure monitoring (ABPM) studies.
  • The existing VTE warning remains; the FDA did not remove or soften the class-wide language about DVT/PE risk.

For men weighing TRT, the 2025 update re-centers attention on individualized cardiovascular and clotting risk assessment: blood pressure management remains important, and the clot warning persists.

Post-marketing reports: strengths and limits

Post-marketing surveillance is essential for uncovering rare or delayed adverse events after a drug is widely used. These reports helped trigger the FDA’s 2014 testosterone labeling changes and remain the backbone of the VTE warning. However:

  • Spontaneous reports do not establish incidence. We learn that events have occurred but not how often they occur compared with similar men not taking TRT.
  • Causality is uncertain. Reports often lack full clinical detail, and confounding factors (immobility, surgery, obesity, smoking, inherited clotting disorders) can overlap with TRT exposure.
  • Underreporting is common. Even significant events are not always reported.

Bottom line: post-marketing data signal a potential connection between testosterone and VTE, sufficient for a warning, but they do not define the exact magnitude of testosterone VTE risk.

What clinical trials do—and don’t—tell us

Large randomized trials provide high-quality evidence for some questions but have limitations for VTE:

  • The TRAVERSE trial primarily focused on MACE among hypogonadal men using topical testosterone versus placebo. Its results informed the 2025 label changes around cardiovascular risk and blood pressure. Available summaries do not provide a definitive, formulation-specific VTE rate.
  • Trials commonly exclude higher-risk patients—such as those with recent VTE or known thrombophilia—making it harder to generalize results to those groups.
  • Other TRT programs consistently note class effects like rises in hematocrit but generally lack dedicated, adequately powered VTE endpoints.

Taken together: randomized trial evidence is more informative for cardiovascular outcomes and hematocrit than for precise VTE rates. Labels continue to emphasize monitoring and clinical vigilance rather than citing a universal VTE incidence number.

Real-world incidence: why a clear number is elusive

Patients and clinicians naturally want a simple answer: “What’s my absolute VTE risk on TRT?” Current sources don’t offer that. Several challenges limit precise estimates:

  • Heterogeneity in TRT formulations, dosing intervals, and target testosterone ranges.
  • Patient selection and comorbidities that differ dramatically between clinics and populations.
  • Variability in hematocrit response (and how aggressively it is managed).
  • Incomplete or passive surveillance outside of clinical trials.

The upshot is that while the testosterone pulmonary embolism and DVT warning is real and relevant, risk appears to be context-dependent and remains difficult to quantify with confidence from the available sources.

Which patients may face higher VTE risk?

While the FDA labeling applies to all users, certain factors may warrant extra caution and shared decision-making:

  • Prior DVT/PE or known thrombophilia; these patients are frequently excluded from TRT trials and may merit specialist input.
  • Family history of unexplained clots, especially at a young age.
  • Conditions that elevate clotting risk: immobility, recent major surgery, obesity, or smoking.
  • Polycythemia (elevated hematocrit). Testosterone can raise hematocrit; higher hematocrit is associated with thrombotic risk.
  • Significant cardiac, hepatic, or renal disease, which can interact with overall risk.

Important context: labels and trial designs encourage caution and monitoring; high-risk patients may still be considered for TRT in select, co-managed scenarios, but this is an individualized decision balancing symptom relief, biochemical deficiency, and safety.

Practical implications if you’re considering or using TRT

  • Clarify diagnosis. Testosterone is indicated for men with confirmed hypogonadism, not for age-related symptoms alone.
  • Share your clotting history. Disclose any personal or family history of DVT/PE or known thrombophilia before starting TRT.
  • Discuss monitoring. Ask how hematocrit and blood pressure will be tracked and which thresholds prompt action.
  • Understand symptoms. Learn potential VTE symptoms so you can seek timely evaluation.
  • Review comorbidities and medicines. Conditions or drugs that raise clotting risk may influence suitability or dosing.
  • Plan for follow-up. Regular follow-up supports safe therapy, especially during titration and the first year.

Recognizing possible DVT/PE symptoms

  • Possible DVT: new, unilateral leg swelling, warmth, redness, or pain—especially in the calf.
  • Possible PE: sudden shortness of breath, chest pain that may worsen with deep breaths, rapid heart rate, coughing up blood, or sudden faintness.

If such symptoms arise, seek urgent medical attention. The FDA label advises prescribers to evaluate for VTE and discontinue testosterone if VTE is suspected; patients should be promptly assessed by a clinician.

Open research questions

  • What is the precise real-world VTE incidence attributable to TRT across diverse populations?
  • Does VTE risk differ by formulation or by achieved testosterone levels?
  • How do TRAVERSE and other contemporary data specifically inform VTE risk, beyond MACE and blood pressure?
  • Should routine thrombophilia screening be considered in select TRT candidates, and which profiles merit testing?

How Taurus Meds approaches safety

  • We prioritize accurate diagnosis of hypogonadism and shared decision-making grounded in FDA labeling and current evidence.
  • We coordinate appropriate monitoring, including hematocrit and blood pressure, and encourage transparent discussion of personal and family clotting history.
  • For men with prior clots or suspected thrombophilia, we support collaborative care with the patient’s clinicians to individualize decisions.

Our goal is to help patients balance symptom relief with prudent risk management, avoiding hype and emphasizing clarity.

Conclusion

The current state of evidence supports a pragmatic view: TRT’s VTE warning is real and rooted in post-marketing experience, yet precise incidence remains uncertain. The 2025 FDA update shifts cardiovascular messaging, underscoring blood pressure effects and retaining the VTE caution. For men with confirmed hypogonadism, the decision to start or continue TRT should incorporate personal risk factors—especially any history of clots or thrombophilia—alongside careful monitoring of hematocrit and blood pressure. With individualized assessment and follow-up, many men can navigate TRT’s benefits and risks responsibly.

Disclaimer

This article is for informational purposes only and is not medical advice. Do not start, stop, or change any medication based on this content. Always consult a qualified healthcare professional about your specific situation.

Sources

Liraglutide vs TRT for Weight Loss in Hypogonadal Men 16-week Trial Results

Posted on by Taurus

Liraglutide vs TRT for Weight Loss in Hypogonadal Men 16-week Trial Results

Estimated reading time: 9 minutes

Key takeaways

  • Liraglutide produced substantially greater 16-week weight loss than TRT (−7.9 kg vs −0.9 kg) with larger reductions in BMI and waist.
  • Both treatments improved total testosterone and hypogonadal symptoms; the testosterone rise was numerically larger with TRT, but between-group differences were not statistically significant.
  • Liraglutide increased LH/FSH, while TRT suppressed them—key for men concerned about fertility and HPT axis recovery.
  • TRT improved insulin resistance (HOMA-IR); liraglutide reduced HbA1c more and resolved metabolic syndrome in some participants.
  • Small, single-center, open-label, 16-week study—long-term durability, safety, and fertility outcomes remain uncertain.

Table of contents

  1. Why this comparison matters
  2. Who was studied
  3. The trial at a glance
  4. Weight, waist, and metabolic health
  5. Symptoms and testosterone
  6. Fertility and the HPT axis
  7. Safety and tolerability
  8. Practical implications
  9. What we still don’t know
  10. How Taurus Meds can support
  11. Bottom line

Why this comparison matters

Obesity-related, or “functional,” hypogonadism is common in men with higher BMI and metabolic risk. When lifestyle changes aren’t enough, men and their clinicians often consider testosterone replacement therapy (TRT). Increasingly, GLP‑1 receptor agonists like liraglutide (at the 3 mg dose used for chronic weight management) are also part of that conversation. A head-to-head clinical trial offers useful signals on how these options compare for weight loss, metabolic health, testosterone, and symptoms over 16 weeks.

GLP‑1 drugs target weight and glycemia—factors tightly linked to testosterone regulation—while TRT directly raises serum testosterone but can suppress the HPT axis and typically does not cause major weight loss. For men prioritizing weight, metabolic risk, symptoms, or future fertility, understanding the trade‑offs is crucial.

Who was studied

  • Adults: 30 men, average age ~46.5 years, with obesity (mean BMI ~41 kg/m²).
  • Diagnosis: Functional hypogonadism with total testosterone <11 nmol/L and symptomatic per validated questionnaires.
  • Prior care: Insufficient response to lifestyle intervention before enrollment.
  • Randomization: Liraglutide 3 mg SC daily vs transdermal 1% testosterone gel 50 mg daily.
  • Duration: 16 weeks with assessments every 4 weeks.

This focused population—obese men with presumed metabolic drivers of low testosterone who struggled with lifestyle change—limits generalizability to other hypogonadism types (e.g., primary testicular failure) or normal‑weight men.

The trial at a glance

Design: Prospective, randomized, open‑label, single‑center study. Randomization supports internal validity, but the open‑label design can influence subjective outcomes. The small sample (n=30) and short duration (16 weeks) constrain precision and long‑term inference.

Primary and monitored outcomes included:

  • Body weight, BMI, and waist circumference
  • Hypogonadal symptom burden (e.g., AMS scores) and sexual function
  • Total testosterone, LH, and FSH
  • Insulin resistance (HOMA‑IR) and glycemic measures (e.g., HbA1c)
  • Presence of metabolic syndrome

Weight, waist, and metabolic health: clear advantage for liraglutide

  • Weight change at 16 weeks:
    • Liraglutide: −7.9 ± 3.8 kg (−6.0 ± 3.2%)
    • TRT: −0.9 ± 4.5 kg (−0.8 ± 3.3%)
  • Central adiposity: Liraglutide significantly reduced waist circumference; TRT changes were modest and not statistically significant.
  • Metabolic syndrome: Resolved in 2/15 on liraglutide vs 0/15 on TRT over 16 weeks.

Insulin/glycemic markers:

  • HOMA‑IR improved (decreased) in the TRT arm.
  • HbA1c improved more with liraglutide.

These results align with GLP‑1 mechanisms: clinically meaningful weight loss and better glycemic control with reductions in central adiposity—a key driver of functional hypogonadism. While TRT improved insulin sensitivity, it did not match liraglutide for weight or waist change over 16 weeks.

Symptoms and testosterone: both improved

Both groups reported improvements in sexual function and hypogonadal symptoms, tracked every four weeks using standardized tools.

  • Total testosterone change at 16 weeks:
    • TRT: +5.9 ± 7.2 nmol/L
    • Liraglutide: +2.6 ± 3.5 nmol/L

Between‑group differences in testosterone were not statistically significant in this small study. TRT directly raises serum testosterone; liraglutide’s gains likely reflect weight/fat loss and improved metabolic milieu.

Fertility and the HPT axis: a key divergence

  • Liraglutide increased LH and FSH (P<0.001 vs TRT), suggesting normalization of central signaling.
  • TRT suppressed LH/FSH, reflecting expected negative feedback on the HPT axis.

Why it matters: Suppressed gonadotropins on TRT can reduce intratesticular testosterone, impair spermatogenesis, and delay fertility recovery after discontinuation. By reducing adiposity and potentially relieving central suppression, a GLP‑1 approach may support endogenous axis recovery rather than suppress it.

Safety and tolerability: what the trial can—and cannot—tell us

This 16‑week, small, open‑label study was not powered for comprehensive safety outcomes. General considerations apply:

  • Liraglutide (3 mg daily):
    • Common: dose‑dependent GI effects (nausea, vomiting, diarrhea), especially during titration.
    • Warnings: pancreatitis risk; certain populations were excluded in the trial.
    • Metabolic: favorable effects on weight/glycemia and cardiovascular risk markers observed in broader GLP‑1 literature.
  • TRT (1% transdermal gel 50 mg daily):
    • Risks: erythrocytosis, acne/oily skin, effects on PSA/prostate, edema, and potential exacerbation of untreated sleep apnea.
    • HPT suppression may impair fertility during treatment.

Because adverse‑event capture is limited here by size and duration, decisions should lean on broader safety data and individual risk profiles.

Practical implications for men considering liraglutide vs TRT

Who might favor liraglutide (GLP‑1 approach)?

  • Men prioritizing weight reduction, waist loss, and metabolic risk improvement.
  • Men wishing to avoid HPT axis suppression and maintain or recover fertility.
  • Those with prediabetes or glycemic concerns who may benefit from HbA1c reduction.

Who might favor TRT?

  • Men seeking a more direct and often faster rise in serum testosterone to relieve hypogonadal symptoms.
  • Men without near‑term fertility goals who accept HPT suppression as part of therapy.
  • Men who have tried or are not candidates for GLP‑1 therapy, or who experience intolerable GLP‑1 side effects.

Monitoring and follow‑up:

  • Symptom tracking every 4–12 weeks (e.g., AMS or similar).
  • Labs: morning total testosterone, SHBG if indicated, LH/FSH, hematocrit/hemoglobin, PSA as age‑appropriate, HbA1c/fasting glucose/HOMA‑IR, lipids.
  • Anthropometrics: weight and waist circumference.
  • Document and revisit fertility goals regularly.

Combination or sequencing? Not addressed by this trial. A practical approach is starting with a GLP‑1 to improve weight/metabolic drivers, then reassessing testosterone and symptoms before initiating or resuming TRT. Evidence for combination therapy is limited and should be individualized.

What we still don’t know

  • Durability beyond 16 weeks for weight loss, symptom relief, and hormonal normalization.
  • Cardiovascular and renal outcomes in this specific population.
  • Fertility outcomes and long‑term HPT recovery with GLP‑1 vs TRT.
  • Comparative data with newer GLP‑1 RAs (e.g., semaglutide; SEMAT trial ongoing).
  • Real‑world adherence, access, cost, and tolerability.
  • Formulation effects: this study used transdermal gel; results may differ with injections or other regimens.

How Taurus Meds can support

Men rarely fit neatly into a single treatment path. At Taurus Meds, we help patients and clinicians explore evidence‑based options—whether prioritizing weight loss, symptom relief, fertility, or all three. We support careful baseline evaluation, shared decision‑making, and structured follow‑up so therapy aligns with each person’s goals and risk profile.

Bottom line

In obese men with functional hypogonadism who did not respond to lifestyle interventions, a 16‑week randomized trial suggests liraglutide 3 mg daily delivers substantially greater weight and waist reduction than TRT, improves hypogonadal symptoms, raises gonadotropins, and can resolve metabolic syndrome in some cases. Both treatments improved testosterone levels and symptoms, with TRT showing a larger numerical increase in total testosterone but at the expected cost of HPT axis suppression.

For many men whose low testosterone is closely tied to excess weight and metabolic dysfunction, a GLP‑1–based strategy may be a strong first step. For others, particularly those seeking rapid testosterone normalization and who are not prioritizing fertility, TRT remains a reasonable option. Because evidence is short‑term and individual goals differ, the best choice is the one made with a clinician who understands both the endocrine and cardiometabolic sides of men’s health.

Disclaimer

This article is for educational purposes only and is not medical advice. Decisions about diagnosing or treating hypogonadism, initiating TRT, or using GLP‑1 therapies should be made with a qualified healthcare professional who can consider your full medical history and goals.

Sources

Endocrine Society TRT Guidelines 2026 What the Evidence Shows

Posted on by Taurus

Endocrine Society TRT Guidelines 2026 What the Evidence Shows

Estimated reading time: ~8 minutes

Key takeaways

  • The Endocrine Society diagnosis requires symptoms plus two separate low early‑morning total testosterone results, typically near a 264 ng/dL lower limit (assay-dependent; some use up to ~300 ng/dL).
  • Most reliable benefits: improved libido/erectile function, correction of otherwise unexplained anemia, and increased spine/hip bone mineral density.
  • Erythrocytosis is the most frequent adverse effect; baseline labs and early monitoring are essential.
  • Trials to date show no clear increase in MACE or prostate cancer, but they are not large/long enough to definitively exclude risk—especially in older men.
  • The VA’s January 2026 guidance aligns with Endocrine Society thresholds and structured monitoring targeting mid‑normal testosterone levels; routine TRT in men ≥65 is not recommended.

Table of contents

  1. What Counts as a Proper TRT Diagnosis in 2026?
  2. Who Should (and Shouldn’t) Consider TRT?
  3. What Benefits Are Most Reliably Supported?
  4. Safety, Risks, and What We Still Don’t Know
  5. Monitoring: The TRT Protocol Most Clinics Still Follow
  6. Where Do Weight Loss and GLP-1 Medications Fit?
  7. What Changed for 2026?
  8. Questions to Discuss With Your Clinician
  9. How Taurus Meds Approaches Care
  10. Conclusion

The Endocrine Society’s most recent clinical practice guideline on testosterone therapy remains the 2018 update, built on systematic reviews and high-quality randomized trials. As we move through 2026, those recommendations still anchor clinical practice—now reinforced by the U.S. Department of Veterans Affairs’ January 2026 clinical recommendations that align with Endocrine Society diagnostic thresholds. This article distills where the evidence is strongest, where uncertainty remains, and what the “TRT guidelines 2026” landscape means for men considering or using testosterone therapy.

What Counts as a Proper TRT Diagnosis in 2026?

The crux of the Endocrine Society’s approach is twofold: symptoms and verified low testosterone.

  • Symptoms: Typical features include reduced libido, erectile dysfunction, decreased morning erections, low energy, decreased muscle mass/strength, or low bone density. No single symptom proves hypogonadism; clinicians assess clusters of signs and their impact.
  • Confirmed low levels: Diagnosis relies on two separate early-morning total testosterone measurements (ideally using a CDC-harmonized assay) obtained on different days, while the patient is stable (not acutely ill).
  • Thresholds: The guideline cites the lower limit of normal around 264 ng/dL for harmonized assays. Some practices use up to approximately 300 ng/dL depending on local lab reference ranges and binding protein (SHBG) considerations.
  • Nuance with SHBG/Free T: In men with suspected binding protein abnormalities (e.g., obesity, diabetes), clinicians may use calculated or measured free testosterone to refine interpretation, but decisions remain symptom- and risk-based.

Bottom line: For 2026, the Endocrine Society’s 2018 diagnostic framework still stands and is echoed in the VA’s January 2026 recommendations. A single borderline lab without symptoms—or symptoms alone without consistently low labs—does not meet criteria.

Who Should (and Shouldn’t) Consider TRT?

The guideline favors TRT for men with confirmed hypogonadism and meaningful symptoms when the expected benefits outweigh risks. However, several groups warrant caution or avoidance:

  • Men ≥65 years: The Endocrine Society recommends against routine TRT due to insufficient long-term randomized data on MACE and prostate cancer in older men. Careful, individualized risk–benefit discussions are essential if therapy is considered.
  • Planning fertility: Exogenous testosterone suppresses spermatogenesis. Men seeking fertility should avoid TRT and discuss alternative strategies with their clinician.
  • High hematocrit: Elevated baseline hematocrit (commonly >48–50%) increases erythrocytosis risk. This is a relative or absolute contraindication depending on severity and clinical context.
  • Prostate/breast cancer: Known prostate or breast cancer is a contraindication. Subclinical prostate disease should be evaluated before starting therapy, consistent with age- and risk-based screening practices.
  • Severe lower urinary tract symptoms (LUTS): An IPSS >19 is generally considered a contraindication until addressed.
  • Untreated obstructive sleep apnea: Untreated OSA is a relative contraindication; evaluation and management of OSA typically precede or accompany TRT.

For men with obesity or type 2 diabetes, clinicians often emphasize weight loss and cardiometabolic optimization first. Weight reduction can raise endogenous testosterone and improve sexual and metabolic health, potentially reducing the need for pharmacologic therapy in some cases.

What Benefits Are Most Reliably Supported?

The Endocrine Society’s systematic reviews and subsequent analyses highlight several consistent benefits in properly diagnosed men:

  • Sexual health: Improvements in libido, erectile function, and overall sexual activity have been shown in randomized trials using validated instruments, particularly among men who meet strict biochemical and clinical criteria.
  • Hematologic benefit: TRT can correct otherwise unexplained anemia in hypogonadal men.
  • Bone health: Trials (including components of the TTrials) show increased volumetric bone mineral density at the spine and hip.
  • Symptoms without strong evidence: Large, well-designed studies have not consistently shown benefits for mood, general vitality, or nonspecific energy when compared with placebo.

Practical implication: Men considering TRT in 2026 should anchor expectations around sexual function, anemia correction, and bone density support—not broad “wellness” claims.

Safety, Risks, and What We Still Don’t Know

  • Erythrocytosis: The most frequent adverse event. Hematocrit >54% generally prompts holding therapy and reassessing dose, route, or contributing factors. Baseline elevation is a red flag.
  • Cardiovascular outcomes: No clear signal of increased MACE has emerged from available randomized trials, but these studies were not powered or long enough to definitively confirm safety. Men at higher cardiovascular risk should have individualized assessments.
  • Prostate cancer: Randomized trials to date do not show increased prostate cancer incidence; however, limited duration and sample sizes prevent firm conclusions. Baseline PSA assessment and early follow-up remain standard.
  • Older men: Uncertainty is greatest for men ≥65. The recommendation against routine initiation in this group reflects evidence gaps, not a proven harm signal. Shared decision-making is critical.

Practical implication: For 2026, the vigilance remains the same—screen thoughtfully, monitor early and regularly, and revisit the risk–benefit balance as clinical status changes.

Monitoring: The TRT Protocol Most Clinics Still Follow

Although exact schedules vary, the Endocrine Society guidance—and the VA’s 2026 clinical recommendations—outline a structured approach:

  • Targets: Aim for mid-normal serum testosterone on the chosen assay, avoiding peaks/troughs that drive side effects.
  • Early labs and visits: Reassess symptoms, testosterone levels, and hematocrit within the first several months after initiation or dose changes.
  • Hematocrit: Check at baseline, again at 3–6 months, and then periodically (often annually) if stable. Address hematocrit >54% promptly.
  • Prostate monitoring: Obtain baseline PSA and perform age/risk-appropriate prostate evaluation before starting. Repeat PSA and prostate assessment during the first year, then follow standard screening thereafter.
  • Adverse effects: Monitor for acne, fluid retention, changes in blood pressure, sleep apnea symptoms, and LUTS. Consider route and dose modifications if issues arise.

Practical implication: If you’re on TRT in 2026, expect more frequent check-ins early on, then a maintenance rhythm—focused on keeping levels steady and safety markers within range.

Where Do Weight Loss and GLP-1 Medications Fit?

Obesity and insulin resistance can suppress endogenous testosterone. Effective weight loss, whether through lifestyle, bariatric approaches, or GLP-1–based therapies, often raises testosterone and improves sexual and metabolic health. Emerging and ongoing research is exploring how anti-obesity medications may change the calculus for hypogonadism management, but definitive head-to-head evidence versus TRT is limited.

  • Confounding and open questions: Because weight loss itself raises testosterone, improvements seen with GLP-1s in men with obesity or type 2 diabetes may reflect recovery of endogenous production rather than a drug-specific androgen effect.
  • Research horizon: Clinical trials are ongoing and may clarify how best to sequence or combine strategies for men with obesity-related hypogonadism.

Practical implication: In 2026, many clinicians will address weight and metabolic health first—both for overall risk reduction and to see whether testosterone normalizes without exogenous therapy.

What Changed for 2026?

  • Endocrine Society: No new 2026 guideline has been released. The 2018 guideline—based on systematic reviews and major RCTs—still guides practice.
  • VA alignment (Jan 2026): The U.S. Department of Veterans Affairs issued updated clinical recommendations that align with Endocrine Society thresholds (lower limit near 264 ng/dL) and reinforce structured monitoring targeting mid-normal testosterone levels.

In practice, this means the core approach to diagnosis, benefits, risks, and monitoring remains stable for 2026, with health systems harmonizing around similar thresholds and follow-up expectations.

Questions to Discuss With Your Clinician

  • Based on my symptoms and two morning labs, do I meet Endocrine Society criteria for hypogonadism?
  • What is the lower limit of normal for my lab’s assay, and how does SHBG affect my results?
  • Do my age, PSA, hematocrit, sleep apnea risk, or urinary symptoms change the risk–benefit balance?
  • If we start, what is our monitoring plan for hematocrit, PSA/prostate health, and dose adjustments?
  • Could addressing weight, sleep, or cardiometabolic health improve my testosterone without TRT—or change the dose I’d need?

How Taurus Meds Approaches Care

At Taurus Meds, we align our protocols with the Endocrine Society’s guidance and the VA’s 2026 recommendations. We prioritize:

  • Clear diagnosis using appropriate assays and repeat morning testing
  • Thoughtful risk assessment (including age, prostate, hematocrit, and cardiometabolic factors)
  • A monitoring plan that aims for mid-normal testosterone while tracking hematocrit, PSA, and symptom response

We also collaborate with patients and their clinicians on lifestyle and metabolic strategies that can support hormonal health—whether or not TRT is ultimately indicated.

Conclusion

For 2026, the “TRT guidelines” picture remains consistent: diagnose hypogonadism carefully using symptoms plus two low morning testosterone results; expect the most reliable benefits in sexual function, anemia correction, and bone density; and monitor closely for erythrocytosis and prostate issues. There is still no definitive randomized-trial evidence tying TRT to increased MACE or prostate cancer, but studies have not been large or long enough to eliminate concern—particularly in older men. Weight loss and metabolic health remain central, both for risk reduction and for their potential to restore endogenous testosterone.

A measured, guideline-based approach—grounded in shared decision-making and vigilant monitoring—continues to be the safest path forward.

Disclaimer

This article is for educational purposes only and is not medical advice. Do not start, stop, or change any medication or testing based on this content. Consult a qualified healthcare professional for individualized evaluation and care.

Sources

TRT Before Bariatric Surgery Evidence for LUTS and Metabolic Prep

Posted on by Taurus

TRT Before Bariatric Surgery Evidence for LUTS and Metabolic Prep

Estimated reading time: 8 minutes

Key Takeaways

  • There are no completed randomized controlled trials of pre-bariatric TRT for LUTS or metabolic outcomes; a prospective protocol (NCT02248467) exists but results are not yet published.
  • Bariatric surgery alone often restores testosterone in men with obesity; about half normalize total T in one 2024 analysis, with sustained free T gains up to five years in men with type 2 diabetes.
  • Early data suggest GLP-1–based therapy can outperform TRT for pre-op weight loss and gonadotropin recovery in obesity-related hypogonadism.
  • If considered, pre-op TRT should follow FDA indications for classical hypogonadism and include monitoring of hematocrit, PSA, and LUTS/IPSS.
  • Open questions remain about TRT’s effects on LUTS, prostate imaging, adipose tissue biology, and meaningful post-surgical outcomes.

Table of Contents

  1. Why low testosterone and LUTS matter before bariatric surgery
  2. The study protocol to watch: NCT02248467
  3. What bariatric surgery alone does to testosterone
  4. Could TRT before surgery help LUTS or metabolic prep?
  5. How GLP-1–based prep compares with TRT
  6. Safety, eligibility, and monitoring considerations
  7. What to discuss with your care team while you wait for surgery
  8. What we still don’t know
  9. A balanced conclusion

For men with obesity, hypogonadism and lower urinary tract symptoms (LUTS) often travel together. As more patients head toward bariatric surgery, interest has grown in whether short-term testosterone replacement therapy (TRT) before surgery could ease LUTS, improve metabolic markers, or even influence adipose tissue function collected during surgery. The short answer: we don’t yet have definitive trial results, but a detailed study protocol exists—and bariatric surgery itself is a powerful driver of testosterone recovery.

This article reviews the current evidence, the standout clinical trial protocol to watch, and how to think about LUTS, metabolic preparation, and safety when considering TRT before bariatric surgery.

Why low testosterone and LUTS matter before bariatric surgery

Obesity is associated with secondary hypogonadism through multiple pathways (e.g., increased aromatization, inflammatory signaling, insulin resistance, sleep apnea). Many of these men also experience LUTS—urinary frequency, urgency, nocturia, weak stream—measured by the International Prostate Symptom Score (IPSS). Moderate LUTS is often defined as IPSS ≥8.

Going into bariatric surgery with untreated hypogonadism may affect energy, sexual health, recovery readiness, and glucometabolic status. Men with significant LUTS may also worry about whether hormonal changes will exacerbate urinary symptoms or prostate issues while awaiting surgery. This is the zone where “TRT before bariatric surgery” becomes a clinically relevant question: could short-term therapy help stabilize symptoms and metabolic risk markers until surgery resets the hormonal landscape?

The study protocol to watch: NCT02248467

A 2014 prospective study protocol from Florence, Italy (NCT02248467) was designed to directly examine this question in a real-world pre-bariatric setting:

  • Population: Obese hypogonadal men (BMI ≥35–40 kg/m²) awaiting bariatric surgery, with total testosterone <12 nmol/L and IPSS ≥8; an eugonadal comparison group was also included.
  • Groups: Symptomatic hypogonadal men treated with TRT (n=25), hypogonadal men not treated with TRT (n=25), and eugonadal men (n=50).
  • Outcomes:
    • LUTS via IPSS and uroflowmetry.
    • Prostate ultrasound parameters (volume, calcifications, arterial velocity).
    • Sexual function (IIEF-5) and aging-male symptoms (AMS).
    • Metabolic markers (glucose, HbA1c, lipids, blood pressure, BMI).
    • Tissue-level biology from adipose samples collected during surgery, including preadipocyte function.
  • Timing: Assessments pre-surgery and up to one year post-surgery.

Important caveats:

  • The TRT arm appears non-randomized and not explicitly placebo-controlled, with dosing reflecting routine practice.
  • Small sample sizes and one-year follow-up may limit power and long-term insights.
  • As of now, no results have been published; study status is unclear.

Why it matters: This protocol uniquely connects symptomatic LUTS, detailed prostate imaging, standard metabolic endpoints, and adipose biology with the real-world journey through bariatric surgery—exactly the evidence men and clinicians need for informed decisions about TRT before surgery.

ClinicalTrials.gov: NCT02248467

What bariatric surgery alone does to testosterone

Independent of TRT, bariatric surgery reliably raises endogenous testosterone in men with obesity. Multiple analyses report meaningful increases:

  • A 2024 study found that roughly 50% of men with obesity and low testosterone normalized after bariatric surgery.
  • Data from a large U.S. center showed sustained increases in free testosterone up to five years postoperatively in men with type 2 diabetes.

Mechanisms likely include weight loss, reduced inflammation, improved insulin sensitivity, and changes in sleep apnea—all of which may restore the hypothalamic-pituitary-gonadal axis. While heterogeneity exists across procedures and patient characteristics, the signal is consistent: weight-loss surgery is one of the strongest “treatments” for obesity-related low T.

Practical implication: Many men considering TRT before bariatric surgery may find that their testosterone improves substantially after surgery—potentially reducing or eliminating the need for long-term TRT. Short-term pre-op TRT, if used, should therefore be weighed against an expected postoperative hormonal rebound.

PubMed: 38958350

Could TRT before surgery help LUTS or metabolic prep?

This is where the evidence gap is most obvious. The NCT02248467 protocol set out to test whether TRT affects:

  • IPSS/LUTS and uroflowmetry pre-op and post-op.
  • Prostate ultrasound findings (gland volume, calcifications, arterial velocity).
  • Metabolic parameters often targeted during “surgery prep” (glycemic control, triglycerides, HDL/LDL, blood pressure, body composition).
  • Preadipocyte function from surgical adipose samples, a rare tissue-level look at how androgens might influence adipose remodeling.

Until results are published, the best we can say is:

  • TRT has shown improvements in components of metabolic syndrome (e.g., waist circumference, triglycerides) in hypogonadal men, but in older obese populations it has not consistently outperformed structured lifestyle therapy.
  • LUTS and prostate outcomes in obese hypogonadal men on TRT remain an open question. Historically, concerns about TRT worsening benign prostatic hyperplasia (BPH) symptoms have been tempered by more recent data showing mixed or neutral effects in many contexts, but this has not been rigorously proven in the pre-bariatric population.
  • Any pre-op TRT trial would need to carefully monitor hematocrit, PSA, and symptom scores, given theoretical risks and perioperative considerations.

Bottom line: The rationale for “TRT before bariatric surgery” is plausible for symptom support and metabolic fine-tuning, but confirmatory data are missing. Decisions should be individualized and aligned with FDA guidance and clinical judgment.

How GLP-1–based prep compares with TRT

Several trials in obese hypogonadal men—outside the surgical setting—suggest that GLP-1–based therapy may be more effective than TRT for pre-op priorities like weight loss and cardiometabolic improvement:

  • In head-to-head comparisons, liraglutide outperformed TRT for weight loss (about 7.9 kg vs 0.9 kg) and for increasing gonadotropins, even though TRT raised serum testosterone.
  • A new trial (SEMAT; NCT06489457) is evaluating semaglutide vs TRT on hypogonadal symptoms, sperm quality, and metabolic parameters in men with type 2 diabetes or obesity.

Implications for surgery prep:

  • If the primary goal before bariatric surgery is weight reduction and glycemic improvement, GLP-1 therapy may deliver larger and faster gains than TRT.
  • Restoring endogenous gonadotropins with weight loss and metabolic therapies can also support hormonal recovery—complementary to the expected testosterone rebound after surgery.
  • This does not negate a role for TRT in men with classical hypogonadism; rather, it highlights that the optimal “prehab” strategy for obesity-linked hypogonadism may prioritize comprehensive metabolic management.

ClinicalTrials.gov: NCT06489457 (SEMAT)

PubMed: 30707677

Safety, eligibility, and monitoring considerations

  • FDA position: TRT is approved for classical hypogonadism (e.g., pituitary/testicular disease), not for age-related or obesity-related low testosterone alone. Off-label use requires a careful risk–benefit discussion.
  • Cardiovascular risk: The 2023 TRAVERSE trial found that TRT was noninferior to placebo for major adverse cardiovascular events in appropriately selected men, but individual risk profiles vary.
  • Perioperative monitoring: Short-term TRT—if pursued—typically warrants checks of hematocrit (erythrocytosis risk), PSA and prostate exam history, and tracking of IPSS/LUTS. Urologic symptoms and prostate ultrasound findings (gland volume, calcifications, arterial velocity) were planned endpoints in NCT02248467 and are reasonable clinical considerations.
  • Generalizability: Protocols often exclude men with very high IPSS or elevated PSA, which may limit how findings apply to real-world patients with more severe LUTS or higher prostate cancer risk.
  • Interactions with lifestyle: Some studies suggest TRT might blunt certain favorable lipid or adipokine changes that come with intensive lifestyle interventions; results are mixed and context-dependent.

In practice, a careful conversation with your surgical, endocrine, and urology team can clarify whether TRT belongs in your pre-surgery plan—or whether weight-centric strategies (nutrition, GLP-1 receptor agonists, sleep apnea management) are the more impactful bridge to surgery.

FDA: Testosterone Information

What to discuss with your care team while you wait for surgery

  • Your hypogonadism type and indication: Do you meet criteria for classical hypogonadism, or is low T likely secondary to obesity and sleep apnea?
  • Near-term goals: Is the priority symptom relief (fatigue, libido), LUTS stabilization, weight optimization, glycemic control—or all of the above?
  • Monitoring plan: If considering TRT, what is the plan for hematocrit, PSA, and IPSS tracking? How would therapy be timed around surgery?
  • Alternatives and complements: Would GLP-1–based therapy, sleep apnea treatment, or intensified nutrition/physical activity yield stronger pre-op gains? Could these reduce the need for TRT after surgery?
  • Post-op expectations: Given high rates of testosterone recovery after bariatric surgery, what is the plan for reassessment and potential de-escalation of therapy?

What we still don’t know

Despite a decade of interest, pivotal questions remain unanswered for TRT before bariatric surgery:

  • Does short-term pre-op TRT improve LUTS (IPSS), uroflowmetry, or prostate ultrasound findings compared with placebo or no treatment?
  • Does pre-op TRT change surgical adipose biology (preadipocyte function) in a way that influences weight loss or metabolic outcomes after surgery?
  • Are any benefits durable after surgery, or do they fade as endogenous testosterone rises?
  • What are the long-term safety signals—including prostate events and cardiovascular outcomes—in men receiving brief pre-op TRT?
  • When will results from NCT02248467 (and related studies, such as trials combining TRT with exercise or comparing TRT to GLP-1 therapy) become available?

A balanced conclusion

For men exploring TRT before bariatric surgery, the most reliable fact is that surgery itself is a potent testosterone normalizer—often within months, and sometimes sustained for years. The open question is whether a carefully monitored, short-term course of TRT meaningfully improves LUTS, prostate parameters, metabolic markers, or tissue-level biology in the lead-up to surgery.

Until trials like NCT02248467 report outcomes, decisions will hinge on individual indication (classical vs secondary hypogonadism), symptom burden, metabolic priorities, and safety considerations. GLP-1–based therapy and comprehensive metabolic prehab currently offer some of the strongest evidence for pre-surgery gains. If TRT is considered, align with FDA guidance, select carefully, and monitor thoughtfully.

At Taurus Meds, our role is to help patients and clinicians navigate the evolving evidence with clear information and coordinated care pathways—without shortcuts or hype.

Disclaimer

This article is for educational purposes only and is not medical advice. Decisions about diagnosis, treatment, or surgery preparation should be made with a qualified healthcare professional who knows your medical history.

Sources

Pediatric Testosterone Therapy FDA Approvals, Evidence Gaps, and Care Standards

Posted on by Taurus

Pediatric Testosterone Therapy FDA Approvals, Evidence Gaps, and Care Standards

Which testosterone treatments are actually FDA-approved for adolescents, and why most others are adult-only. Understand growth plate risks, monitoring, and where new studies may lead.

Estimated reading time: 8 minutes

Key takeaways

  • Only testosterone enanthate injections and subcutaneous pellets carry FDA indications related to delayed puberty in carefully selected males or for hypogonadism occurring before puberty; most modern TRT products are adult-only.
  • These pediatric indications predate current trial standards and would not meet today’s evidentiary expectations.
  • Labels warn of accelerated bone age and premature epiphyseal closure; bone-age X-rays about every six months are recommended when used in adolescents.
  • Kyzatrex (oral testosterone undecanoate) has an FDA postmarketing requirement to study pediatric males 12 to <18—an effort to fill evidence gaps.
  • Clinicians and families should confirm the narrow FDA-recognized indications, involve pediatric endocrinology, monitor growth plates, and avoid off-label pediatric use of other formulations.

Table of contents

  1. What the FDA Actually Approves for Pediatric Use Today
  2. Why These Legacy Pediatric Approvals Don’t Look Like Modern Trials
  3. Risks Unique to Adolescents: Bone Age Acceleration and Growth Plates
  4. Kyzatrex’s Pediatric PMR: A Modern Study to Close a Long‑Standing Gap
  5. Practical Implications for Clinicians and Families
  6. How Modern Standards May Evolve
  7. A Balanced Conclusion

Testosterone therapy in adolescents sits at a careful intersection of endocrinology, growth, and regulation. The FDA does allow select testosterone formulations for pediatric use—but only in narrow circumstances and based largely on historical approvals that would not meet today’s evidentiary standards. This article reviews what’s actually FDA‑approved for delayed puberty or pediatric hypogonadism, why the evidence base looks different from modern trials, the specific risks relevant to adolescents, and what to watch as new pediatric studies are required for newer products.

What the FDA Actually Approves for Pediatric Use Today

Despite the broad public conversation about testosterone therapy, pediatric approvals are narrow:

  • Testosterone enanthate (TE) injections and subcutaneous testosterone pellets have FDA labeling that permits use “for stimulating puberty in carefully selected males with clear evidence of delayed puberty,” or for hypogonadism occurring prior to puberty.
  • The labels emphasize cautious patient selection and monitoring. They recommend bone‑age (hand/wrist) radiographs about every six months during treatment to watch for accelerated bone maturation.
  • In contrast, nearly all other testosterone replacement therapy (TRT) products—transdermal gels and patches, short‑acting nasal formulations, injectable testosterone undecanoate, and oral testosterone undecanoate—explicitly state that safety and efficacy have not been established in males younger than 18 years. In other words, they’re adult‑only, with pediatric use not supported by current labeling.

This matters because clinical practice and direct‑to‑consumer marketing for adult hypogonadism can be mistaken for a green light in adolescents. It isn’t. For pediatric patients, FDA‑recognized options are limited to TE injections and pellets, and even those require vigilant growth monitoring and specialist oversight.

Why These Legacy Pediatric Approvals Don’t Look Like Modern Trials

The TE and pellet approvals trace back to an earlier regulatory era. Historically, the concept was straightforward: if a child has hypogonadism or markedly delayed puberty, androgen replacement can stimulate the development of secondary sexual characteristics. That principle underpinned the approvals—without the type of well‑controlled, adequately powered pediatric efficacy and safety trials that the FDA typically expects today.

Key context:

  • Many testosterone products were introduced before the Drug Efficacy Study Implementation (DESI) modernized standards for proof of efficacy. As a result, historical approvals leaned more on pharmacology and clinical experience than on contemporary randomized trial designs.
  • Modern adult TRT approvals tend to rely on pharmacokinetic (PK) “normalization”—showing that a product achieves serum testosterone levels within adult reference ranges—rather than on hard clinical outcomes. In pediatrics, however, growth, maturation timing, bone health, and long‑term development carry different stakes and require dedicated study.
  • Because the original pediatric approvals didn’t go through today’s trial rigor, we lack robust, contemporary data on long‑term growth outcomes, optimal regimens across hypogonadism subtypes, or comparative effectiveness among formulations in adolescents.

In short, the existence of a pediatric indication for TE and pellets reflects regulatory history, not a comprehensive modern evidence base.

Risks Unique to Adolescents: Bone Age Acceleration and Growth Plates

The clearest label warning for adolescent testosterone exposure is the risk of accelerated bone maturation leading to premature epiphyseal closure. In practical terms, the growth plates in long bones can fuse earlier than they otherwise would, potentially limiting final adult height.

What this means for care:

  • Monitoring is not optional. Bone‑age X‑rays roughly every six months are part of responsible care when using TE injections or pellets in adolescents. Radiographic evidence of advancement beyond expected maturity may prompt reassessment.
  • “Improper use” is a real concern. Initiating therapy in the absence of clear hypogonadism or carefully selected delayed puberty—or using supraphysiologic amounts—raises the risk of rapid skeletal maturation without proportional linear growth.
  • Individual variation matters. Adolescents are in a dynamic developmental window with evolving endocrine, skeletal, and psychosocial trajectories. Decisions about whether and when to start or adjust therapy require pediatric endocrinology expertise and careful discussion of benefits, risks, and uncertainties.

Other androgen‑related adverse effects (like acne, mood changes, or hematologic shifts) may occur, but the growth plate risk is uniquely consequential for lifelong stature and underpins the strict monitoring recommendations.

Kyzatrex’s Pediatric PMR: A Modern Study to Close a Long‑Standing Gap

Kyzatrex (oral testosterone undecanoate) was approved by the FDA in 2022 for adult hypogonadism. Importantly for pediatrics, its approval includes a postmarketing requirement to conduct a pediatric trial in males ages 12 to <18 with primary or secondary hypogonadism. The PMR milestones specified at approval were:

  • Study protocol submission: June 2023
  • Trial completion: December 2023
  • Final report submission: March 2024

Why this matters:

  • It’s a deliberate move by the FDA to generate modern pediatric data where little currently exists, particularly for oral testosterone formulations.
  • A dedicated pediatric study—if well designed and completed—could clarify dosing strategies, safety signals (including growth plate impacts), PK targets appropriate for adolescents, and short‑term clinical effects (e.g., Tanner staging progress).
  • Even with new data, a pediatric indication is not guaranteed. The FDA could conclude that safety/efficacy remain insufficient, that benefits apply only to specific subgroups, or that additional studies are needed.

As of the 2022 approval, results were not available. Families and clinicians should check the latest FDA communications to confirm whether the PMR has been completed, what it found, and whether it changes labeling or recommendations.

Practical Implications for Clinicians and Families

Given the tight regulatory framework and evidence gaps, a conservative, standards‑based approach is warranted.

If a pediatric patient is being evaluated for delayed puberty or suspected hypogonadism:

  • Confirm the diagnosis with a pediatric endocrinologist. The differential for delayed puberty is broad, and timing of maturation varies. Specialist input helps determine whether observation, non‑androgen strategies, or androgen therapy is appropriate.
  • Verify the FDA‑approved pediatric options. As of now, only TE injections and subcutaneous pellets have pediatric‑relevant indications for stimulating puberty in carefully selected cases. Most other TRT formulations explicitly lack pediatric safety/efficacy data.
  • Discuss growth plate monitoring upfront. Bone‑age radiographs about every six months are part of the label recommendations to mitigate the risk of premature epiphyseal closure.
  • Align expectations with uncertainties. Short‑term progression of secondary sexual characteristics may be achievable, but the long‑term impact on adult height, cardiometabolic health, fertility, and psychosocial outcomes remains under‑studied by modern standards.
  • Approach off‑label pediatric use of adult‑only products with caution. The absence of established safety and efficacy is meaningful; approval in adults does not imply suitability for adolescents.
  • Reassess regularly. Adolescence is a moving target. Periodic review of growth velocity, bone age, Tanner staging, labs, and psychosocial factors supports course corrections as needed.

Questions families can bring to a pediatric endocrinology visit:

  • Is my child’s presentation consistent with constitutional delay, or is there evidence of primary/secondary hypogonadism?
  • If testosterone is considered, why TE injections or pellets versus other formulations? What’s FDA‑approved for pediatric use?
  • How will bone maturation and growth be monitored? What would trigger a change in plan?
  • What short‑term benefits should we expect, and what are the known and unknown risks?
  • How does the plan align with my child’s developmental, social, and athletic life?
  • If newer data (e.g., from required pediatric studies) become available, how would that impact the treatment approach?

For adult‑focused TRT clinics, including services like Taurus Meds, the practical boundary is clear: pediatric therapy requires pediatric endocrinology expertise, pediatric‑specific monitoring, and adherence to FDA‑recognized indications. Adult TRT workflows and formulations shouldn’t be repurposed for adolescents.

How Modern Standards May Evolve

Two regulatory dynamics will shape the future of pediatric TRT:

  • Pediatric research requirements and incentives: For newer products approved in adults, the FDA can require pediatric assessments or studies if a therapy might be relevant to children. That’s the case with Kyzatrex. As more data emerge, labeling could expand—or remain restricted—based on benefits and risks demonstrated in adolescents.
  • Outcome expectations: Pediatric trials increasingly emphasize clinically meaningful outcomes—growth trajectories, bone age progression relative to chronological age, pubertal staging, safety signals—rather than PK alone. This could raise the evidentiary bar for future pediatric indications across formulations.

Key open questions:

  • Will modern pediatric trials confirm safe, effective regimens that preserve adult height potential?
  • Are certain hypogonadism subtypes better suited to specific formulations or schedules?
  • Can findings from adult PK‑normalization translate safely to adolescents, or do youth‑specific targets and endpoints need to be defined?
  • What is the long‑term safety profile of contemporary formulations started during adolescence?

A Balanced Conclusion

Pediatric TRT is not a simple extension of adult practice. Today, only testosterone enanthate injections and testosterone pellets hold FDA indications relevant to delayed puberty in carefully selected cases, and those approvals stem from an earlier regulatory era. The label‑mandated focus on bone‑age monitoring reflects a real and potentially irreversible risk: premature closure of the growth plates.

Newer products approved for adults—like Kyzatrex—are now carrying postmarketing pediatric study requirements, which is a welcome step toward an evidence base aligned with modern standards. Until high‑quality pediatric data are available and acted upon through updated labeling, clinicians and families should stay within the narrow FDA‑recognized indications, avoid off‑label pediatric use of adult‑only formulations, and partner closely with pediatric endocrinologists.

For families exploring care options, the safest path is a measured one—grounded in diagnosis, respectful of growth biology, and responsive to new data as it emerges.

Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice. Testosterone therapy in adolescents should be managed by qualified healthcare professionals—ideally pediatric endocrinologists—based on individual clinical circumstances and current FDA‑approved labeling.

Sources